IMAX CORP

(a)None.

(b)None.

(c)Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements.

On September 10, 2026, Robert D. Lister, the Company’s Chief Legal Officer & Senior Executive Vice President, entered into a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K under the Exchange Act (“Item 408”) and such arrangement, the “Lister Plan”) for the sale of up to 30,000 common shares of the Company. Sales under the Lister Plan, which was previously disclosed in a Company subsidiary filing, may commence on December 10, 2026, after the completion of the required cooling off period under Rule 10b5-1. The Lister Plan will terminate on June 9, 2027, or earlier if all shares under the Lister Plan have been sold. This trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).

On September 14, 2026, Richard Gelfond, the CEO, entered into a Rule 10b5-1 trading arrangement (as defined in Item 408 and such arrangement, the “Gelfond Plan”) for (i) the sale of 200,000 common shares; (ii) the exercise of 522,979 of stock options granted in January 2019 (the “Options”), which are due to expire on January 2, 2029, and the sale of up to 522,979 common shares underlying the Options; and (iii) the sale of an additional undetermined number of common shares to be received by Mr. Gelfond upon the vesting of 722,979 RSUs on January 4, 2027 (continuing to hold well in excess of his share ownership guidelines). Sales under this Gelfond Plan, which was previously disclosed in a Company subsidiary filing, may commence on December 21, 2026, after the completion of the required cooling-off period under Rule 10b5-1. The Gelfond Plan will terminate on June 25, 2027, or earlier if all shares under the Gelfond Plan have been sold. This trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c).

On September 14, 2026, Natasha Fernandes, the Company’s Chief Financial Officer, terminated a Rule 10b5-1 trading arrangement adopted on June 26, 2026 that was intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 30,000 common shares of the Company. As of the date of termination, Ms. Fernandes had not sold any common shares under the plan.

No other Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as defined in Item 408) were adopted orterminated by any directors or officers of the Company during the third quarter of 2026.